Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System

Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System

Propeller Health is collaborating with Dignity Health (formerly Catholic Healthcare West (CHW)) to carry out a focused demonstration project to evaluate the effectiveness and potential cost savings of a deployment of the Propeller Health approach to asthma management. The Propeller Health goal is to bring together the best technology and asthma insight in order to provide Dignity Health with an engaging, data-driven chronic care program to improve asthma management and lower healthcare utilization costs, and to respond to prevention-focused reforms to health insurance laws.

This project has been designed to implement and evaluate a data-driven program to improve asthma management and control and lower direct costs through reductions in healthcare utilization. This program has been developed by Propeller Health and has gone through preliminary testing. Each subject participating in the study will receive an Propeller Health device, which captures the time and location of use of inhaled short-acting bronchodilators over a twelve-month period. This information is processed and delivered at regular intervals to the patient and his or her provider to support improved asthma management.

The purpose of the study is to evaluate the impact of the adoption of the Propeller Health system into a healthcare organization, and to provide sufficient information to inform decision making for potential future adopters. The researchers believe that the Propeller Health system has the potential to improve asthma control by providing rescue inhaler actuation data and tailored asthma management tips to patients with uncontrolled asthma, and rescue inhaler actuation data to their providers. Improvements in asthma control should be reflected in reductions in healthcare utilization for asthma, and potentially for general healthcare utilization. Reductions in utilization would result in lower healthcare costs. The study has been designed to capture data on individual subject asthma control, and changes in utilization and costs over a one-year introduction period.

Inclusion Criteria:

• Provider diagnosis of asthma (ICD9 493.xx);
• At least one healthcare utilization event in CHW within last 12 months; and
• Prescription for Short Acting Beta Agonist (SABA) at study intake.

Exclusion Criteria:

• Subject is under the age of 5 at the beginning of the study;
• Subject does not speak either English or Spanish;
• Subject does not have access to the Internet or email to receive reports; and
• Subject has substantial co-morbidity (provider diagnosis of COPD